What if diagnosing Multiple Sclerosis was as simple as a blood test?
Today, it still isn’t. Multiple sclerosis (MS) remains one of the most difficult neurological diseases to diagnose. There is no specific test, and the current process relies on multiple clinical tests—MRIs, lumbar punctures, evoked potentials—that can take months to complete. In many cases, patients wait up to a year for a diagnosis. Furthermore, its symptoms overlap with those of more than 100 other diseases, leading to frequent misdiagnosis. For this reason, MS is known as “the disease of a thousand faces.”
In Multiple Sclerosis, every month counts
Current treatments, such as disease-modifying drugs or immunomodulators, can slow and even halt the progression of the disease, but they cannot reverse neurological damage once it has set in. Early diagnosis is key to starting treatment before the most severe symptoms appear, which translates into a better quality of life for the patient. Currently, such early diagnosis is not possible. ALA Diagnostics aims to change that.
A paradigm shift is underway
ALA Diagnostics develops in vitro tests for diseases with unmet medical needs. Our first product is a noninvasive test for diagnosing Multiple Sclerosis, which is applicable to the early diagnosis of the disease. We have already clinically validated the unique biomarker on which it is based in two studies with a total of 598 patients. In addition, we have developed and validated a proprietary diagnostic algorithm that has demonstrated sensitivity and specificity exceeding 90%.
This year, our test will enter an international clinical trial in Europe and the US, which will allow us to obtain the clinical validation necessary for commercialization in 2026. The protocol design is already finalized, and preparation for the study is underway.
Key advantages of the test:
- Non-invasive, blood-based
- Fast: results in hours
- Economical: up to 95% reduction compared to current methods
- Reliable: Combined with our algorithm, it has a sensitivity and specificity greater than 90%.
Unique technology with no direct competition
Our biomarker is patent-protected, and the freedom-to-operate (FTO) analysis of our latest patent family has already been completed. To date, there are no direct competitors with such a simple, reliable, and clinically validated solution. Furthermore, we have already established initial contacts with multinational companies in the in vitro diagnostics sector regarding future collaborations or licensing.
Experienced team and support network
We have a team with extensive clinical and business experience, a strong network of contacts with key opinion leaders (KOLs), medical and patient associations, industry, and regulatory agencies. We are ready to execute the next phase.
We are at the moment of greatest value creation
We are now looking for strategic partners to help us complete the clinical phase and prepare the test launch in 2026. Over the past two years, we have already achieved several clinical milestones, and currently, €900k is required to finalise this stage. Of this total, €500k is committed by BeAble Capital and several private investors, while the remaining €400k is being raised through Capital Cell, aiming to bring in small investors who want to become key shareholders and support us at this crucial moment.
Investing in ALA Diagnostics today means participating in a paradigm shift in neurological diagnostics.
